Rilshield
Antiretroviral
About
Rilshield® is a brand of Rilpivirine, a high potency second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV/AIDS. It is recommended for patients with a viral load of 100,000 copies/mL or less at the beginning of therapy. Rilshield® is a registered trademark of Carpa Healthcare limited.
Administration
Rilshield® is available in tablet form, each film-coated tablet contains rilpivirine hydrochloride equivalent to 25 mg rilpivirine. Each film-coated tablet contains 56 mg lactose monohydrate. Rilshield should be administered orally as recommended by a physician.
Pediatrics (12 to 17 years)
One tablet of 25 mg Rilshield® is recommended to be taken with a meal once daily
Pregnancy and Postpartum
The recommended dosage of Rilshield® for pregnant patients is one 25 mg tablet taken orally once daily with food. As reduced rilpivirine exposure has been observed during pregnancy, close monitoring of viral load is advised throughout treatment.
Side Effects
The most common side effects of Rilshield® tablets may include depressive disorders (4.1%), headache (3.5%), insomnia (3.5%) and rashes (2.3%) when combined with one or more other antiretroviral drugs.
Prescription Information
Rilshield® in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve adult patients. Rilshield® in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve pediatric patients 12 to less than 18 years of age with a viral load of ≤100000 HIV-1 RNA copies/mL. Rilshield must always be given in combination with other antiretroviral medicinal products. Please consult your physician for tailored prescriptions.
